STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα Russian patent published in 2019 - IPC C07K16/24 A61K39/395 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, in particular to an aqueous composition for the treatment of TNFα-associated disease in a mammal comprising an effective amount of the antibody or its antigen-binding fragment, which binds specifically to human TNFα, where the antibody or its antigen-binding fragment contains the sequence of the human variable framework region of the heavy chain and the sequence CDR H1, CDR H2 and CDR H3, derived from rabbit antibody that specifically binds to human TNFα, where the human variable framework region of the heavy chain has at least 90 % identity with SEQ ID NO: 2, and the sequence of the human variable framework region of the light chain and sequence CDR L1, CDR L2 and CDR L3, derived from rabbit antibody that specifically binds to human TNFα, where the human light chain variable region has at least 90 % identity with SEQ ID NO: 1, and where the human variable framework region of the heavy chain has at least one of the following amino acids: threonine (T) at position 24, valine (V) at position 25, alanine (A) or glycine (G) at position 56, lysine (K) at position 82, threonine (T) at position 84, valine (V) at position 89 and arginine (R) at position 108 (AHo numbering), where the concentration of the antibody or antibody fragment in the composition is from about 0.1 up to about 50 mg/ml.

EFFECT: invention improves the effectiveness of the treatment of TNFα-associated disease in a mammal.

18 cl, 12 dwg, 6 tbl, 6 ex